Genomics Boom Boosts Sales of Research Tools

Genomics and Medicine: transformative therapies are coming but diagnostic breakthroughs will lead the way Ten years after the start of the Human Genome Project  we have learned a lot about the links between genetics and disease but few direct cures have emerged. The biotech Company Human Genome Sciences(HGSI), an early player in genome discovery has […]

Continue Reading 0

Rayno Life Science Portfolio Update: Finally a Rally Day

Any momentum in biotech stocks from ASCO have been eclipsed by bearish, volatile trends overall.  There were some nice moves up today with the Rayno Life Science Portfolio was up 2.67% and all bio ETF’s did well: FBT up 3%,XBI up 3.48%, and IBB up 3.11%. Among the big movers in the Rayno Portfolio were: […]

Continue Reading 0

ASCO: Little Help for Biotech Stocks

Two Big Winners in Bristol Myers Squibb and Celgene The American Society of Oncology Meeting is normally good times for biotech as scientific and clinical developments propel stocks. This year the personalized medicine theme with potential breakthroughs in  targeted therapy for cancer is expected show excellent clinical results. In advance of ASCO Bristol Myers(BMY) presented […]

Continue Reading 0

Cubist (CBST) Pharmaceuticals Up 3% on Heavy Volume

In a nasty market where many indices are down 2.5% or more Cubist bucks the trend up 3% apparently on a Cowen and Co. upgrade from Neutral to Outperform.As of midday trading with a Volume of 2.8M shares the stock is at $22.25 up from $21.5 yesterday. The stock is up this year reaching a […]

Continue Reading 0

Genetic Testing Gets a Boost From Medco(MHS)

Diagnostic Medicine is on the Forefront Genetic tests and the new field of pharmacogenomics is getting marketing support from an unlikely source-Pharmacy Benefit Managers (PBM’s). Medco (MHS), a $60B revenue PBM ($26B Market Cap)with over 65M members has been developing a strategy for “personalized medicine” backed by recent acquisitions and partnerships with the Mayo Clinic […]

Continue Reading 0

Pathway Genomics Makes Giant Marketing Step in Personalized Medicine

Genotyping on a Fast Track Direct to Consumer Pathway Genomics is offering a “Health Kit” that reports your genetic risk for 70 diseases such as Cancer,Cardiovascular Disease,RA,and Diabetes. Disease carrier status is included as well as potential genetic interactions with commonly used medications such as Coumadin, Statins and Plavix. A “Saliva Collection Kit” will be […]

Continue Reading 0

Response Genetics(RGDX) Signs Agreement with Glaxo for BRAF Gene

Response Genetics(RGDX) announced a deal today for a non-exclusive license to provide GlaxoSmithKline (GSK) with certain rights to proprietary BRAF mutational analysis technology in human tumor samples. The BRAF gene encodes a protein involved in cell signaling and cellular growth and differentiation.Specific gene mutations have been correlated with the development of certain forms of cancer. […]

Continue Reading 0

Biomarkers Drive Personalized Medicine

Companion Diagnostics Enable More Targeted Therapy At the 2010 BIO Conference in Chicago with about 15,000 attendees there were ten Breakout Sessions on Biomarkers (BM) encompassing Intellectual Property, commercialization, reimbursement, drug development and diagnostics. This explosive new technology niche, is a nascent paradigm for exploiting breakthroughs in the molecular basis of disease and more targeted […]

Continue Reading 0

Dendreon(DNDN) Receives FDA Approval for Therapeutic Cancer Vaccine

New Treatment Category for Cancer-Autologous Cellular Immunotherapy The FDA cleared the first therapeutic vaccine for cancer with Dendreon’s Provenge (R)(Sipuleucel-T), an individualized treatment approach for advanced prostate cancer (CRPC). CRPC is asymptomatic or minimally symptomatic, metastatic,castrate-resistant (hormone refractory) prostate cancer.Provenge takes the patient’s own immune cells and infuses them back thereby priming the immune system […]

Continue Reading 0

Milken Institute Global Conference-Healthcare Reform I

Missed Opportunity in Health Reform-Wellness and Prevention On Monday April 26 a panel of executives  and leaders including Michael Milken, moderated by CNBC anchor Maria Bartiromo convened to discuss Health Reform in a session focused on “Prevention and Cures”. The primary focus of the discussion was the need for government policy and health reform to […]

Continue Reading 0